Transcenta Holding Limited announces that it has received approvals from China CDE and South Korea MFDS to initiate TranStar 301 global Phase III pivotal trial of Osemitamab in combination with Nivolumab and chemotherapy for the first-line treatment of patients with HER2 negative, CLDN18.2 expressing locally advanced or metastatic gastric or gastroesophageal adenocarcinoma.
